Neuropathies aiguës sévères induites par l’infection à SARS-CoV-2 [Acute severe neuropathies in the context of SARS-CoV-2 infection]

Détails

Ressource 1Télécharger: RMS_Neuropathies aigues sévères induites.pdf (136.62 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_FDBFA32A2C10
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Neuropathies aiguës sévères induites par l’infection à SARS-CoV-2 [Acute severe neuropathies in the context of SARS-CoV-2 infection]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Epiney J.B., Bernard-Valnet R., Kuntzer T.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
28/04/2021
Peer-reviewed
Oui
Volume
17
Numéro
736
Pages
828-830
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Various neuromuscular complications have been described in SARS-CoV-2 infection, especially Guillain-Barré syndrome (GBS) and Critical Illness neuromyopathy (CI-NM). Two representative cases are discussed below. It appears that GBS shares most of the characteristics of classical post-infectious GBS, but SARS-CoV-2 may contribute to the increased incidence of CI-NM. Other rare complications have been described, including Tapia Syndrome and Kawasaki-like multiple system inflammatory syndrome. The question of vaccination and the risk of immune-mediated neuropathies remains open, but the lack of reported cases is reassuring as these complications usually occur within 6 weeks after vaccination.
Mots-clé
Brain Diseases, COVID-19, Guillain-Barre Syndrome/epidemiology, Guillain-Barre Syndrome/etiology, Humans, SARS-CoV-2
Pubmed
Création de la notice
19/05/2021 14:11
Dernière modification de la notice
16/01/2024 8:14
Données d'usage